دورية أكاديمية
Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study
| العنوان: | Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study |
|---|---|
| المؤلفون: | V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii |
| المصدر: | Научно-практическая ревматология, Vol 59, Iss 2, Pp 141-151 (2021) |
| بيانات النشر: | IMA PRESS LLC, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Diseases of the musculoskeletal system |
| مصطلحات موضوعية: | levilimab, monoclonal anti-il-6 receptor antibody, rheumatoid arthritis, Diseases of the musculoskeletal system, RC925-935 |
| الوصف: | Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (MTX) resistant patients with active rheumatoid arthritis (RA).Materials and methods. 105 patients with active RA were randomized in a 1:1:1 ratio into two LVL or placebo groups. LVL was administered subcutaneously at a dose of 162 mg every week (QW) or every other week (Q2W). All patients received MTX. After evaluating the primary endpoint of 20% improvement in ACR criteria (ACR20) at week 12, patients in the placebo group were switched to LVL Q2W. The study duration was 56 weeks. The frequency, profile, degree and severity of adverse events were determined in each group for safety assessment. The immunogenicity of LVL was determined by the proportion of patients with identified binding and neutralizing antidrug antibodies. Results. LVL in both regimens was superior to placebo. At week 12, the incidence of ACR20 achievement was 77.1% (LVL QW), 57.1% (LVL Q2W), and 17.1% (placebo) with 95% confidence intervals [37.53; 82.54] (p |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Russian |
| تدمد: | 1995-4484 1995-4492 |
| Relation: | https://rsp.mediar-press.net/rsp/article/view/3016; https://doaj.org/toc/1995-4484; https://doaj.org/toc/1995-4492 |
| DOI: | 10.47360/1995-4484-2021-141-151 |
| URL الوصول: | https://doaj.org/article/b875e4d7b7464abf86d0680266117122 |
| رقم الأكسشن: | edsdoj.b875e4d7b7464abf86d0680266117122 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19954484 19954492 |
|---|---|
| DOI: | 10.47360/1995-4484-2021-141-151 |